Publications by authors named "K Wlotzka"
Article Synopsis
- Glioblastoma (GB) is currently incurable, and this study tested the safety and feasibility of using HER2-targeted chimeric antigen receptor (CAR)-NK cells in patients with recurrent GB, aiming to find a treatment option.
- Nine patients received varying doses of irradiated CAR-NK cells during surgery for their recurrent HER2-positive GB, and a range of follow-up analyses were conducted to assess the immune response and treatment effects.
- The results showed no severe side effects from the treatment, with some patients experiencing stable disease for weeks, and the study determined that the maximum safe dose of CAR-NK cells for further trials is 1 × 108 cells.
Glioblastoma (GB) is the most common primary brain tumor, which is characterized by low immunogenicity of tumor cells and prevalent immunosuppression in the tumor microenvironment (TME). Targeted local combination immunotherapy is a promising strategy to overcome these obstacles. Here, we evaluated tumor-cell specific delivery of an anti-PD-1 immunoadhesin (aPD-1) via a targeted adeno-associated viral vector (AAV) as well as HER2-specific NK-92/5.
View Article and Find Full Text PDF